Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2016-08-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于2016年半年度募集资金实际存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the actual storage and usage of funds raised in the first half of 2016 by 福安药业（集团）股份有限公司. It includes extensive financial data on fundraising amounts, usage, bank accounts, investment projects, changes in investment projects, and compliance with regulatory requirements. The document references regulatory approvals from the China Securities Regulatory Commission and includes detailed tables and explanations about the use of raised funds, including superfluous funds and their management. The document is lengthy (15,000 characters) and contains substantive financial data and analysis related to fundraising and capital usage. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. It is not an announcement of a report, nor a full annual or interim report, but a specialized report on fundraising and capital usage. Therefore, the appropriate classification is CAP with high confidence.
2016-08-26 Chinese
独立董事关于第三届董事会第十次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the company's third board of directors' tenth meeting, specifically addressing the half-year period of 2016. It includes statements about the use of funds, guarantees, and compliance with regulations related to the half-year fundraising and fund usage. The document is not a full interim or quarterly report but rather an independent opinion or certification related to the half-year report and fundraising compliance. It does not contain substantive financial data or detailed financial statements itself. Given the nature of the document as an independent directors' opinion on specific governance and compliance matters, it fits best under Regulatory Filings (RNS), which covers certifications, attestations, and miscellaneous regulatory documents that do not constitute full financial reports.
2016-08-26 Chinese
2016年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "福安药业（集团）股份有限公司 2016 年半年度报告全文" which translates to "Fuan Pharmaceutical (Group) Co., Ltd. 2016 Semi-Annual Report Full Text." It contains detailed financial data, including revenue, net profit, cash flow, assets, liabilities, and management discussion of business operations and risks. The document includes comprehensive financial statements and analysis for a period shorter than a full fiscal year (half-year). The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2016
2016-08-26 Chinese
关于公司控股股东部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a major shareholder of the company 福安药业 (Fuan Pharmaceutical Group Co., Ltd.). It details the number of shares pledged, the dates, the pledgee, and the percentage of shares involved. There is no financial report, earnings data, or management discussion. The content is about a shareholder's share pledge, which relates to capital structure but is specifically about share pledging by a controlling shareholder. This fits best under Capital/Financing Update (CAP) as it concerns financing activities related to share pledges by a major shareholder. The document length is short and it is not an announcement of a report publication or a certification, so it is not RPA or RNS.
2016-08-26 Chinese
第三届监事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 福安药业 regarding their meeting held on August 26, 2016. It includes the Supervisory Board's review and approval of the company's 2016 semi-annual report and its summary, as well as other related agenda items. The document states the Supervisory Board's opinion that the semi-annual report complies with relevant laws and regulations and reflects the company's actual operating conditions. The document is not the semi-annual report itself but a formal announcement of the Supervisory Board's approval and opinions on the report. Given the nature of the document as a meeting resolution and approval announcement rather than the report itself, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories. The document length is short (877 characters), and it does not contain the actual financial statements or detailed financial data, so it is not an Interim/Quarterly Report (IR).
2016-08-26 Chinese
关于公司投资设立子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 福安药业（集团）股份有限公司 regarding the company's investment to establish a wholly-owned subsidiary. It details the purpose, basic information about the new subsidiary, the investment amount, and the board resolution approving the investment. The document is relatively short (1714 characters) and focuses on the investment and corporate restructuring rather than providing financial statements or detailed financial performance data. It is not a full financial report, audit report, or earnings release. It is also not a regulatory certification or voting result announcement. The content fits best with a Capital/Financing Update (CAP) as it concerns company fundraising and capital structure changes through the establishment of a new subsidiary and asset transfer.
2016-08-26 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.